Giorgio Ivan Russo1, Giovanni Cacciamani2, Andrea Cocci3, Thomas M Kessler4, Giuseppe Morgia5, Ege Can Serefoglu6, Maarten Albersen7, Paolo Verze8. 1. Urology section-University of Catania, Catania, Italy. Electronic address: giorgioivan1987@gmail.com. 2. Urologic Clinic, University of Verona, Verona, Italy. 3. Department of Urology, University of Florence, Italy. 4. Department of Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland. 5. Urology section-University of Catania, Catania, Italy. 6. Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey. 7. Department of Urology, University Hospitals Leuven, Leuven, Belgium. 8. Department of Neurosciences, Reproductive Sciences, Odontostomatology, Urology Unit, University of Naples, Naples, Italy.
Abstract
INTRODUCTION: Medical treatment of Peyronie's disease (PD) in terms of intralesional therapy is still a matter of debate. AIM: To compare the efficacy of different classes of intralesional therapy with a network meta-analysis (NMA) method. METHODS: The search was conducted using documents published in PubMed, Scopus, and Web of Science databases until September 30, 2017. We included randomized controlled trials comparing at least 1 intralesional therapy with a placebo therapy or with another drug for the treatment of PD. All intralesional therapies have been considered: collagenase Clostridium histolyticum (CCH), hyaluronic acid, verapamil, and interferon α-2b. MAIN OUTCOME MEASURE: Outcomes of the study are the mean change in penile curvature (PC) and in erectile function (EF) assessed with the International Index of Erectile Function questionnaire. RESULTS: In total, 8 comparisons matched with the inclusion criteria, which includes 1,050 patients. With regard to PC (degree) improvement, hyaluronic acid and verapamil showed worse outcomes when compared with CCH (-6.66 and -2.30) and interferon α-2b (-6.75 and -2.38). When considering improvement in EF, hyaluronic acid, verapamil and interferon α-2b showed a slight increase in mean change when compared with CCH (+2.39, +1.77, and +0.65). Moreover, verapamil and interferon α-2b showed slightly worse mean change in comparison to hyaluronic acid (+0.62 and +1.74), whereas interferon α-2b was worse than verapamil (-1.12). CLINICAL IMPLICATIONS: Based on this NMA, empirical therapy for PD should be avoided to offer the patients the best treatment in terms of level of evidence. STRENGTHS & LIMITATIONS: In this NMA, we have provided, for the first time, evidence of the efficacy between different intralesional therapies for the treatment of PD. We were not able to compare all specific outcomes (ie, pain, plaque size, patient satisfaction) of PD, because of the lack of homogeneity across relevant studies. Moreover, because of the few included studies, a meta-regression analysis of predictive factors of treatment response was not calculated. CONCLUSION: This is the first meta-analysis comparing all available intralesional treatments for PD. CCH and interferon α-2b showed the best outcome in terms of PC, whereas hyaluronic acid was most efficient in relation to EF. Russo GI, Cacciamani G, Cocci A, et al. Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. J Sex Med 2019;16:289-299.
INTRODUCTION: Medical treatment of Peyronie's disease (PD) in terms of intralesional therapy is still a matter of debate. AIM: To compare the efficacy of different classes of intralesional therapy with a network meta-analysis (NMA) method. METHODS: The search was conducted using documents published in PubMed, Scopus, and Web of Science databases until September 30, 2017. We included randomized controlled trials comparing at least 1 intralesional therapy with a placebo therapy or with another drug for the treatment of PD. All intralesional therapies have been considered: collagenase Clostridium histolyticum (CCH), hyaluronic acid, verapamil, and interferon α-2b. MAIN OUTCOME MEASURE: Outcomes of the study are the mean change in penile curvature (PC) and in erectile function (EF) assessed with the International Index of Erectile Function questionnaire. RESULTS: In total, 8 comparisons matched with the inclusion criteria, which includes 1,050 patients. With regard to PC (degree) improvement, hyaluronic acid and verapamil showed worse outcomes when compared with CCH (-6.66 and -2.30) and interferon α-2b (-6.75 and -2.38). When considering improvement in EF, hyaluronic acid, verapamil and interferon α-2b showed a slight increase in mean change when compared with CCH (+2.39, +1.77, and +0.65). Moreover, verapamil and interferon α-2b showed slightly worse mean change in comparison to hyaluronic acid (+0.62 and +1.74), whereas interferon α-2b was worse than verapamil (-1.12). CLINICAL IMPLICATIONS: Based on this NMA, empirical therapy for PD should be avoided to offer the patients the best treatment in terms of level of evidence. STRENGTHS & LIMITATIONS: In this NMA, we have provided, for the first time, evidence of the efficacy between different intralesional therapies for the treatment of PD. We were not able to compare all specific outcomes (ie, pain, plaque size, patient satisfaction) of PD, because of the lack of homogeneity across relevant studies. Moreover, because of the few included studies, a meta-regression analysis of predictive factors of treatment response was not calculated. CONCLUSION: This is the first meta-analysis comparing all available intralesional treatments for PD. CCH and interferon α-2b showed the best outcome in terms of PC, whereas hyaluronic acid was most efficient in relation to EF. Russo GI, Cacciamani G, Cocci A, et al. Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. J Sex Med 2019;16:289-299.
Authors: Edoardo Pozzi; Paolo Capogrosso; Luca Boeri; Walter Cazzaniga; Rayan Matloob; Eugenio Ventimiglia; Davide Oreggia; Nicolò Schifano; Luigi Candela; Costantino Abbate; Francesco Montorsi; Andrea Salonia Journal: Int J Impot Res Date: 2020-07-01 Impact factor: 2.896
Authors: Raevti Bole; Harrison Chase Gottlich; Matthew J Ziegelmann; Dillon Corrigan; Laurence A Levine; John P Mulhall; Petar Bajic Journal: J Sex Med Date: 2022-02-15 Impact factor: 3.937
Authors: Andrea Cocci; David Ralph; Rados Djinovic; Georgios Hatzichristodoulou; Girolamo Morelli; Andrea Salonia; Paolo Capogrosso; Andrea Romano; Gianmartin Cito; Fabrizio Di Maida; Esaú Fernández-Pascual; Javier Romero-Otero; Paulo Egydio; Marco Falcone; Mirko Preto; Giovanni Chiriacò; Jack Beck; Maarten Albersen; Suks Minhas; Giovanni Cacciamani; Juan Ignacio Martinez Salamanca; Nicola Mondani; Andrea Minervini; Giorgio Ivan Russo Journal: Sci Rep Date: 2021-01-08 Impact factor: 4.379
Authors: Andrea Cocci; Fabrizio Di Maida; Gianmartin Cito; Pierangelo Verrienti; Nicola Laruccia; Riccardo Campi; Andrea Mari; Marina Di Mauro; Marco Falcone; Giovanni E Cacciamani; Giulio Garaffa; Andrea Minervini; Giorgio Ivan Russo Journal: World J Mens Health Date: 2020-01-20 Impact factor: 5.400